Johnson & Johnson’s Ebola Research Gets $115M
International Business Times
Published Jan 16, 2015 09:31AM ET
Updated Jan 16, 2015 10:15AM ET
Johnson & Johnson’s Ebola Research Gets $115M
By Kathleen Caulderwood -
Johnson & Johnson will receive $115 million to support its Ebola vaccine research through a private-public partnership, the company said on Friday.
The money comes from Europe’s Innovative Medicines Initiative (IMI), and is meant to speed up development and testing of J&J’s drug through a newly created consortium that includes the London School of Hygiene and Tropical Medicine, the University of Oxford and La Centre Muraz.
“In the face of the global challenge of Ebola, bringing together the expertise and capabilities of the pharmaceutical industry, academic centers and NGOs will be critical to help solve this crisis,” Paul Stoffels, Johnson & Johnson’s worldwide chairman of pharmaceuticals, said in a Friday statement. “The European Commission’s support through IMI bolsters collaboration that should significantly accelerate efforts to help address this human crisis.”
The worst Ebola outbreak in history has killed more than 8,200 people and infected more than 20,000 in Guinea, Liberia and Sierra Leone since it started last year.
Despite the fact that Ebola outbreaks have been occurring for decades, the commercial incentive for large companies to research it didn’t exist, because of the low number of patients.
“A profit-driven industry does not invest in products for markets that cannot pay,” World Health Organization Director-General Dr. Margaret Chan said in November. “Because Ebola has historically been confined to poor African nations, the R&D incentive is virtually nonexistent.”
But in recent months, some of the world’s largest pharmaceutical companies have become big players in the fight against Ebola.
In October, J&J committed $200 million to Ebola research and began testing its drug in humans on Jan. 6 after producing more than 400,000 doses last year.
The vaccine regimen is made up of two different parts injections -- one from Crucell Holland B.V. and Denmark’s Bavarian Nordic.
Johnson & Johnson isn’t the only company working on Ebola. GlaxoSmithKline is planning to begin human trials in five countries this February and Merck started its own trials in December, though recently lowered its dosage after volunteers experienced joint pain.
Chimerix started testing its Ebola drug on patients in Liberia earlier this month, in partnership with Oxford University and Doctors Without Borders.
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.